These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37701117)

  • 1. The predictive implication of programmed cell death ligand 1 expression in extranodal natural killer/T-Cell lymphoma and its correlation with clinicopathological features: a systematic review and meta-analysis.
    Li W; Zheng Q; Luo X; Zhang X; Zheng X; Yang Y
    Transl Cancer Res; 2023 Aug; 12(8):2115-2127. PubMed ID: 37701117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic value of programmed cell death ligand 1 expression in non-Hodgkin lymphoma: a meta-analysis.
    Zhao S; Zhang M; Zhang Y; Meng H; Wang Y; Liu Y; Jing J; Huang L; Sun M; Zhang Y; Zhang Q
    Cancer Biol Med; 2018 Aug; 15(3):290-298. PubMed ID: 30197796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis.
    Kim WY; Jung HY; Nam SJ; Kim TM; Heo DS; Kim CW; Jeon YK
    Virchows Arch; 2016 Nov; 469(5):581-590. PubMed ID: 27595782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: a meta-analysis.
    Xian F; Ren D; Bie J; Xu G
    Front Immunol; 2023; 14():1119168. PubMed ID: 37138876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prevalence and prognostic and clinicopathological value of PD-L1 and PD-L2 in renal cell carcinoma patients: a systematic review and meta-analysis involving 3,389 patients.
    Lu Y; Song Y; Xu Y; Ou N; Liang Z; Hu R; Zhang W; Kang J; Wang X; Liu L; Yang Y; Liu X
    Transl Androl Urol; 2020 Apr; 9(2):367-381. PubMed ID: 32420142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type.
    Jo JC; Kim M; Choi Y; Kim HJ; Kim JE; Chae SW; Kim H; Cha HJ
    Ann Hematol; 2017 Jan; 96(1):25-31. PubMed ID: 27696202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting treatment response of patients with extranodal natural killer/T-cell lymphoma based on levels of PD-L1 mRNA and soluble PD-L1.
    Feng Y; Jing C; Yu X; Cao X; Xu C
    Hematol Oncol; 2020 Oct; 38(4):467-477. PubMed ID: 32515093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A New Immunological Prognostic Model Based on Immunohistochemistry for Extranodal Natural Killer/T-Cell Lymphoma Patients After Non-Anthracycline-Based Chemotherapy.
    Lam ST; Huang H; Fang X; Wang Z; Hong H; Ren Q; Tian Y; Lin S; Lin T
    Cancer Manag Res; 2020; 12():1981-1990. PubMed ID: 32231439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of programmed cell death ligand-1 expression in ovarian cancer: an updated meta-analysis.
    Piao J; Lim HJ; Lee M
    Obstet Gynecol Sci; 2020 May; 63(3):346-356. PubMed ID: 32489980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The expression and clinical significance of programmed cell death receptor 1 and its ligand in tumor tissues of patients with extranodal nasal NK/T cell lymphoma.
    Feng Y; Feng X; Jing C; Yu X; Zheng Y; Xu C
    Sci Rep; 2022 Jan; 12(1):36. PubMed ID: 34996890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of PD-L1 Expression in Prediction and Stratification of Recurrent or Refractory Extranodal Natural Killer/T-Cell Lymphoma.
    Gao LM; Zhang YH; Shi X; Liu Y; Wang J; Zhang WY; Liu WP
    Front Oncol; 2022; 12():821918. PubMed ID: 35619907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and Clinicopathological Value of Programmed Cell Death Ligand1 Expression in Patients With Small Cell Lung Cancer: A Meta-Analysis.
    Cai H; Zhang H; Jiang Y
    Front Oncol; 2020; 10():1079. PubMed ID: 32670887
    [No Abstract]   [Full Text] [Related]  

  • 14. Programmed Cell Death 1 and Programmed Cell Death Ligands in Extranodal Natural Killer/T Cell Lymphoma: Expression Pattern and Potential Prognostic Relevance.
    Muhamad H; Suksawai N; Assanasen T; Polprasert C; Bunworasate U; Wudhikarn K
    Acta Haematol; 2020; 143(1):78-88. PubMed ID: 31330525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis.
    Li J; Wang P; Xu Y
    PLoS One; 2017; 12(6):e0179536. PubMed ID: 28604812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Function of Programmed Cell Death-Ligand 1 in Esophageal Squamous Cell Carcinoma Patients Without Preoperative Therapy: A Systematic Review and Meta-Analysis.
    Cui H; Li Y; Li S; Liu G
    Front Oncol; 2021; 11():693886. PubMed ID: 34490091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.
    Ouyang Y; Liu W; Zhang N; Yang X; Li J; Long S
    Cancer Med; 2021 Oct; 10(20):7021-7039. PubMed ID: 34423578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Clinicopathological and Prognostic Value of PD-L1 Expression in Cholangiocarcinoma: A Meta-Analysis.
    Xu G; Sun L; Li Y; Xie F; Zhou X; Yang H; Du S; Xu H; Mao Y
    Front Oncol; 2019; 9():897. PubMed ID: 31620360
    [No Abstract]   [Full Text] [Related]  

  • 19. The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis.
    Li Y; Huang Q; Zhou Y; He M; Chen J; Gao Y; Wang X
    Front Pharmacol; 2018; 9():1494. PubMed ID: 30733677
    [No Abstract]   [Full Text] [Related]  

  • 20. A pooled analysis of the prognostic value of PD-L1 in melanoma: evidence from 1062 patients.
    Yang J; Dong M; Shui Y; Zhang Y; Zhang Z; Mi Y; Zuo X; Jiang L; Liu K; Liu Z; Gu X; Shi Y
    Cancer Cell Int; 2020; 20():96. PubMed ID: 32256205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.